Clinical Trials Logo

Clinical Trial Summary

Although allogeneic hematopoietic stem cell transplantation (HSCT) is a curative treatment option for acute leukemia (AL), relapsed or refractory (R/R) AL is still a big challenge. It is believed that decreased tumor burden before HSCT is a favourable factor contributing to the long-term survival of R/R patients and many kinds of bridging chemotherapy regimens were devised to kill leukemic cells before HSCT, there is still no consensus that which regimen is optimal. This study is to investigate the curative efficacy and safty of bridging CAV (cladribine combined with venetoclax and low dose Ara-C ) regimens followed by HSCT treatment proctocal for R/R AML.

Clinical Trial Description


Study Design

Related Conditions & MeSH terms

NCT number NCT05190549
Study type Interventional
Source The First Affiliated Hospital of Soochow University
Contact Sheng-Li Xue, M.D.
Phone 008651267781139
Email [email protected]
Status Recruiting
Phase Phase 2
Start date October 1, 2021
Completion date October 1, 2023